In this issue:
- Prebiologic disease trajectories: morbidity burden and response in severe asthma
- Patient-centred composite scores for assessing biologic response in severe asthma
- Inflammatory and clinical risk factors for asthma attacks
- Burden of asthma and atopic dermatitis 1990–2021, and out to 2050
- Phenotyping systemic corticosteroid responses in asthma attack management
- As-needed salbutamol budesonide in mild asthma
- Associations of ICS dose with adverse events
- Respiratory research in Māori and Pacific children in NZ
- Inflammation-induced loss of CFTR-expressing ionocytes in noneosinophilic asthma
- Type 1 immune responses related to viral infection affect corticosteroid response in asthma
- Lunsekimig for asthma
- Mepolizumab response trajectories in severe eosinophilic asthma
- Response/on-treatment remission with tezepelumab for severe, uncontrolled asthma
- Bronchial biopsy for predicting response to biologics in severe uncontrolled asthma
Please login below to download this issue (PDF)